Caremark Selected Provider for Aralast.
BIRMINGHAM, Ala.--(BUSINESS WIRE)--June 4, 2003
Caremark Rx, Inc. (NYSE: CMX) today announced that its affiliate, Caremark Inc. has been selected by Baxter Healthcare Corporation, as one of three providers of Aralast(TM), a new alpha-1 proteinase inhibitor (human).
Aralast(TM) is the second in a class of therapies that serves to treat individuals with alpha-1 proteinase inhibitor deficiency or A1PI.
Caremark specialty pharmacy programs not only provide timely, accurate and confidential dispensing of medications through a network of 17 specialty pharmacies accredited by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO), but also improve outcomes through proactive compliance and persistency monitoring, disease education and pharmacy care management programs.
About Caremark Rx, Inc.
Caremark Rx, Inc. is a leading pharmaceutical services company, providing comprehensive drug benefit services through its affiliate Caremark Inc. to over 1,200 health plan sponsors and their participants throughout the U.S. Caremark's clients include corporate health plans, managed care organizations, insurance companies, unions, government agencies and other funded benefit plans. The company operates a national retail pharmacy network with over 55,000 participating pharmacies, four state-of-the-art mail service pharmacies, the industry's only FDA-regulated repackaging plant and nineteen specialty distribution mail service pharmacies for delivery of advanced medications to individuals with chronic or genetic diseases and disorders.
Additional information about Caremark Rx is available on the World Wide Web at www.caremarkrx.com.
Aralast(TM) is a trademark of Alpha Therapeutic Corporation
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 4, 2003|
|Previous Article:||S&P Assigns SLM Student Loan Trust 2003-6 Prelim Rtgs.|
|Next Article:||The Aristotle Corporation Acquires Haan Crafts Corporation.|